Go back

International group to analyse pharmaceutical company mergers

Regulators will look into whether mergers cause higher drug prices, lower innovation or anticompetitive conduct

An international team of regulators from the EU, Canada, UK and United States has formed a working group to evaluate mergers in the pharmaceutical industry, and whether they have negative effects.

The initiative, announced on 16 March, is a joint effort from authorities including the European Commission’s competition department, the Canadian Competition Bureau, the UK’s Competition and Markets Authority and the US Department of Justice.

This article is only available to *Research Professional subscribers. If you are a subscriber you can read the article in full on researchprofessional.com

Alternatively, Pivot-RP users can log in and view the article via this link.